Loading
A phase 1/2 trial of Atezolizumab, Gemcitabine and Trifluridine/tipiracil in anal cancer and pancreatic ductal adenocarcinoma, run by Oncolytics Biotech, active and no longer recruiting.
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab is a phase 1/2 interventional study registered as NCT07280377 by Oncolytics Biotech, with 122 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil and mFOLFIRINOX Treatment Regimen.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/